Exploring the value of theragnostic radionuclide therapies
within advanced oncology
The 3rd Targeted Radiopharmaceuticals (TRP) Summit returns at a crucial time for the entire industry. Spurred on by positive Phase III VISION trial data, there has been huge research investment, on both sides of the Atlantic, on how to deliver radiation therapy directly and specifically to tumours.
For the 2021 edition of this conference, there will be the opportunity to attend either in-person in Berlin or remotely via a dedicated digital networking platform with all the access to the conference content.
You can expect a wider array of insights from recent case studies to help you accelerate the development of the next generation of radioligand therapies from clinical approval to commercialisation.
As the only industry-led platform for discussing challenges and opportunities facing developers of theranostic radioligand therapies, we strive to tackle topics that are on every drug developer’s mind:
- How do we identify and validate new targets?
- Can we combine Targeted Radiopharmaceuticals with immunotherapy or other targeted oncology methods?
- How do we improve current clinical design methodologies and patient selection strategies?
- Where can improvements be made to the current supply and fulfilment models?
To see the wide variety of talks, panels and speakers tackling these issues, download the full event guide here
Expert Speakers Include:
What Past Attendees Have Said:
Proud to Partner With:
Health & Safety
The health, safety and well-being of our community remains our highest priority. Therefore, all attendees will be required to complete a health declaration prior to attending the event. As part of this, attendees must declare that they are either fully vaccinated and /or have completed a negative Lateral Flow Test or PCR Test within 48 hours the event*. For further information around Health and Safety onsite, please visit our FAQ here.
*Please note, this is subject to change at any time without prior notice.